{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:30:19Z","timestamp":1789655419408,"version":"4.0.1"},"reference-count":45,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Funded by Pfizer"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2217\/fon-2022-1249","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:40:12Z","timestamp":1696952412000},"page":"653-663","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR\n            <i>BRAF<\/i>\n            V600E-mutant mCRC"],"prefix":"10.1080","volume":"20","author":[{"given":"Elena","family":"Elez","sequence":"first","affiliation":[{"name":"Vall d\u2019Hebron Hospital Campus &amp; Vall d\u2019Hebron Institute of Oncology, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Hospital Campus &amp; Vall d\u2019Hebron Institute of Oncology, Universitat de Vic - Universitat Central de Catalunya, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"Georges Pompidou European Hospital, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulam","family":"Manji","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center &amp; NewYork-Presbyterian Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development-Oncology, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Abbattista","sequence":"additional","affiliation":[{"name":"Pfizer Global Product Development-Oncology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van K","family":"Morris","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu260"},{"key":"e_1_3_9_5_1","unstructured":"US FDA . US Food and Drug Administration Approves First-Line Immunotherapy for Patients with MSI-H\/dMMR Metastatic Colorectal Cancer (2022). www.fda.gov\/news-events\/press-announcements\/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer#:\u223c:text=MSI%2DH%20and%20dMMR%20tumors MSI%2DH%20or%20dMMR%20tumors"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.1067"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3051"},{"issue":"3","key":"e_1_3_9_9_1","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y","year":"2020","unstructured":"Han Y , LiuD , LiL. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res10(3), 727\u2013742 (2020).","journal-title":"Am J Cancer Res"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20325-0"},{"key":"e_1_3_9_11_1","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu J","year":"2021","unstructured":"Liu J , ChenZ , LiY , ZhaoW , WuJ , ZhangZ. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol12, (2021).","journal-title":"Front Pharmacol"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004822"},{"key":"e_1_3_9_13_1","unstructured":"Merck & Co. Inc. A Key to More Possibilities for Treating Your Patients: KEYTRUDA Is Approved to Treat 16 Types of Advanced Cancer (2022). www.keytrudahcp.com\/"},{"key":"e_1_3_9_14_1","doi-asserted-by":"crossref","unstructured":"Merck & Co. Inc. A Breakthrough Immunotherapy That May Help You Face Your Cancer (2022). www.keytruda.com\/","DOI":"10.18574\/nyu\/9780814737996.001.0001"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0557"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100145"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101122"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.0996"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131046"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt173"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.010"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0341"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10868"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2779"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00233-7"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.206"},{"key":"e_1_3_9_32_1","volume-title":"BRAFTOVI (encorafenib). Summary of Product Characteristics. EPAR Product Information.","year":"2020","unstructured":"BRAFTOVI (encorafenib). Summary of Product Characteristics. EPAR Product Information. EMA, Amsterdam, Netherlands (2020)."},{"key":"e_1_3_9_33_1","volume-title":"BRAFTOVI (encorafenib). US Prescribing Information.","year":"2020","unstructured":"BRAFTOVI (encorafenib). US Prescribing Information. Array BioPharma Inc., a wholly owned subsidiary of Pfizer Inc., Boulder, CO, USA (2020)."},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.022"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.119"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051848"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2479"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66236"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0531-z"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0215"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.016"},{"key":"e_1_3_9_45_1","volume-title":"KEYTRUDA (pembrolizumab). Summary of Product Characteristics. EPAR Product Information.","year":"2020","unstructured":"KEYTRUDA (pembrolizumab). Summary of Product Characteristics. EPAR Product Information. EMA. Amsterdam, Netherlands (2020)."},{"key":"e_1_3_9_46_1","volume-title":"KEYTRUDA (pembrolizumab). US Prescribing Information.","year":"2020","unstructured":"KEYTRUDA (pembrolizumab). US Prescribing Information. Merck Sharp & Dohme LLC. Rahway, NJ, USA (2020)."},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.012"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:22:01Z","timestamp":1726755721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2217\/fon-2022-1249"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1249","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}